Respiratory Protocol

Overview

The respiratory tract is the body's largest mucosal surface and a primary interface with environmental pathogens, pollutants, and allergens. The lungs employ a sophisticated defense system — the mucociliary escalator, antimicrobial peptides in airway surface liquid, resident alveolar macrophages, and secretory IgA — to maintain sterility of the lower airways while continuously filtering thousands of liters of air daily.

When these defenses are compromised or overwhelmed, the result can be recurrent respiratory infections, chronic bronchitis, post-infectious respiratory damage, or persistent airway inflammation. This protocol applies LL-37 (the human cathelicidin antimicrobial peptide) and thymosin alpha-1 (Ta1) to support respiratory mucosal immunity, address chronic or recurrent airway infections, and promote post-infectious lung recovery.

For broader immune system rebalancing, see the Immune Reset Protocol. For general immune support, see the Immune Support Protocol.

Compounds Involved

LL-37 in Respiratory Context

LL-37 is the only human cathelicidin antimicrobial peptide and is naturally expressed in airway epithelial cells, neutrophils, and alveolar macrophages as a critical component of innate respiratory defense. Its relevance to respiratory health includes direct killing of respiratory pathogens (including drug-resistant bacteria, mycobacteria, respiratory viruses, and fungi), disruption of bacterial biofilms that form in chronic respiratory infections (bronchiectasis, chronic sinusitis), modulation of inflammatory cytokine release in airway tissue, and promotion of epithelial wound healing in damaged airways.

LL-37 expression is upregulated by vitamin D — a key reason why vitamin D optimization is foundational to this protocol.

Thymosin Alpha-1 in Respiratory Context

Thymosin alpha-1 supports respiratory immunity through the adaptive immune arm. Ta1 promotes maturation of T lymphocytes involved in pathogen clearance, enhances natural killer cell cytotoxicity against virus-infected cells, supports dendritic cell function for antigen presentation, and modulates the Th1/Th2 balance (relevant for both infection clearance and allergic airway disease).

Ta1 has been studied in the context of hepatitis and as an adjunct to cancer immunotherapy, and more recently gained attention for its potential role in respiratory viral infections including COVID-19.

Protocol Structure

Phase 1: Foundation (Weeks 1–2)

Optimize the nutritional and mucolytic foundation before introducing peptides.

Daily protocol:

Vitamin D target: 50–70 ng/mL (25-OH vitamin D). This level has been associated with optimal cathelicidin expression. Many individuals with recurrent respiratory infections are vitamin D deficient.

NAC rationale: Beyond its role as a glutathione precursor, NAC is a clinically established mucolytic — it directly breaks disulfide bonds in mucus glycoproteins, thinning secretions and improving mucociliary clearance. This is particularly valuable in chronic bronchitis, bronchiectasis, and post-infectious mucus retention.

Phase 2: Peptide Introduction (Weeks 3–10)

Standard respiratory protocol:

Administration notes:

• LL-37 is typically administered subcutaneously in the abdominal area
• LL-37 courses are kept to 4–6 weeks due to limited long-term safety data
• Ta1 can be continued beyond the LL-37 course
• Injection site reactions (redness, warmth) are common with LL-37 and reflect its immune-activating properties

Phase 3: Maintenance (Weeks 11+)

After the initial treatment course:

LL-37 repeat courses: If symptoms or infections recur, LL-37 courses can be repeated after a 4-week break. Cycling pattern: 4–6 weeks on, 4 weeks off. See Peptide Cycling.

Specific Applications

Chronic Sinusitis

Chronic sinusitis often involves bacterial biofilms in the sinus cavities — structured bacterial communities that resist conventional antibiotics. LL-37's biofilm-disrupting properties make it particularly relevant. The standard SubQ protocol above provides systemic LL-37, but some practitioners have explored nebulized delivery (research stage only — not established for safety in this route). NAC nasal irrigation (saline with NAC) can serve as a local adjunct for mucus clearance.

Post-Infectious Lung Recovery

Following pneumonia, severe bronchitis, or viral respiratory illness (including COVID-19), the lungs may take weeks to months to fully recover. This protocol supports recovery through the anti-inflammatory effects of Ta1, LL-37's tissue repair promotion, NAC's mucolytic and antioxidant support, and gradual respiratory rehabilitation.

Combine with the Brain Fog Protocol if post-infectious cognitive symptoms are present.

Recurrent Upper Respiratory Infections

For individuals who experience frequent colds or respiratory infections (more than 3–4 per year), the immune-modulating effects of Ta1 combined with vitamin D optimization and LL-37's antimicrobial properties target both innate and adaptive immune responses. This is also a context where the Immune Reset Protocol may be appropriate.

Breathing and Respiratory Rehabilitation

Peptide protocols work best when combined with respiratory function optimization:

• Diaphragmatic breathing: Many individuals habitually breathe using accessory muscles rather than the diaphragm, resulting in shallow, inefficient ventilation. Practice 5–10 minutes of focused diaphragmatic breathing daily.
• Nasal breathing: The nose filters, humidifies, and warms inspired air, and nasal breathing produces nitric oxide (a natural antimicrobial and bronchodilator). Prioritize nasal breathing during rest and light exercise.
• Graded aerobic exercise: Progressive cardiovascular exercise improves respiratory efficiency and lung perfusion. Start with walking and gradually progress.
• Humidity management: Dry air impairs mucociliary clearance. Use a humidifier during dry seasons (target 40–60% humidity).
• Air quality: HEPA air purifiers reduce particulate exposure. Avoid smoke, strong chemical fumes, and heavily polluted environments.

Important Considerations

• Rule out serious pathology: Chronic cough, hemoptysis (coughing blood), unexplained weight loss, or progressive dyspnea require proper medical evaluation including imaging and pulmonary function testing. Peptides do not replace medical workup.
• LL-37 and autoimmunity: LL-37 has been implicated in some autoimmune conditions (particularly psoriasis) where it can form complexes with DNA that activate plasmacytoid dendritic cells. Use cautiously in individuals with autoimmune history.
• Not for acute infections: During active pneumonia or severe respiratory infection, standard medical care (antibiotics, antivirals, supportive care) takes priority. This protocol is for chronic support and post-infection recovery.
• Nebulization safety: Nebulized peptide delivery is experimental. Do not attempt to nebulize injectable peptides without direct medical supervision and appropriately formulated preparations.
• Quality: See Purity and Testing for peptide sourcing.

Disclaimer

This article is for educational and informational purposes only. It does not constitute medical advice, and no therapeutic claims are made. Peptide research is ongoing, and individual outcomes may vary. Consult a qualified healthcare professional before beginning any peptide protocol. All compounds discussed are intended for research purposes.